Inovio is revolutionizing the fight against cancer and infectious diseases. Our immunotherapies uniquely activate best-in-class immune responses to prevent and treat disease, including HPV-caused pre-cancers and cancers, prostate cancer, breast, lung, and pancreatic cancers, HIV, and hepatitis. In 2014 we achieved a ground-breaking milestone for the company and the field of active immunotherapies, showing clinically significant efficacy in a phase II clinical study. Partners and collaborators Roche, MedImmune, the University of Pennsylvania, DARPA, Drexel University, NIH, HIV Vaccines Trial Network, National Cancer Institute, U.S. Military HIV Research Program, US Dept. of Homeland Security, and University of Manitoba.